Latest Headlines

  1. Chromacode Announces Partnership With Medgenome To Bring HDPCR-Based Diagnostics To India And The Middle East 4/27/2023

    ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients and physicians, announced today a partnership with MedGenome, to bring its innovative High Definition PCR (HDPCR™) multiplexing technology to India and the Middle East.

  2. Quest Diagnostics To Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology For Improving Personalized Cancer Care To Oncology Portfolio 4/27/2023

    Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, and Haystack Oncology, an early-stage oncology company focused on minimal residual disease (MRD) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisions, today announced a definitive agreement for Quest to acquire Haystack in an all-cash equity transaction.

  3. AccessDx Laboratory Launches Innovative UTI PROx Panel 4/26/2023

    AccessDx Laboratory, a global provider of advanced laboratory diagnostics solutions, today announced general availability of the UTI PROx Panel.

  4. SinguLab® Announces Enhancements To UTI Management Solution 4/26/2023

    SinguLab®, a leading provider of turnkey diagnostic-based solutions for the healthcare industry, today announced enhancements to its suite of capabilities and services that assist clinical providers in the effective treatment and management of Urinary Tract Infections ("UTIs").

  5. Mainz Biomed Announces Partnership With The Instituto De Microecologia To Expand Coloalert® Commercialization In Spain And Portugal 4/26/2023

    Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has added the Instituto de Microecologia in Madrid to its growing network of lab partners across Europe and in select international markets.

  6. FDA Accelerated Approval Of Tofersen Highlights Importance Of Blood Neurofilament Light Chain As Surrogate Endpoint In Neurology Therapeutic Trials 4/25/2023

    Quanterix Corporation a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that blood-based NfL measurements provided compelling support for the FDA’s accelerated approval of tofersen for treatment of superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a devastating rare genetic form of ALS.

  7. Indica Labs And Lunit Announce A Strategic Alliance For Seamless Integrated Digital Pathology AI Workflows 4/25/2023

    Indica Labs, an industry leader in quantitative digital pathology and image management innovations, and Lunit, a leading medical AI software platform company focused on cancer biomarkers announced an agreement to provide a fully interoperable solution between Indica Labs' HALO AP® image management software platform and Lunit's suite of AI pathology products.

  8. Strata Oncology Announces Launch And Medicare Coverage For Strata Select, A First-Of-Its-Kind Immunotherapy Test 4/25/2023

    Strata Oncology, Inc. ("Strata"), a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the launch of Strata Select™, a first-of-its-kind molecular profiling test for patients with advanced cancer.

  9. QIAGEN Launches Qiastat-Dx In Japan With Respiratory Panel For Syndromic Testing 4/24/2023

    QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that its QIAstat-Dx syndromic testing solution is expected to be available soon for use in Japan with a SARS-CoV-2 Respiratory Panel that can detect more than 20 pathogens from a single patient sample.

  10. Alercell Launches ‘Lena Molecular Diagnostic Leukemia Platform’ 4/24/2023

    ALERCELL, INC. announced today that it has introduced a molecular Leukemia diagnostic platform. LENA Molecular Dx Leukemia Platform is a core group of 12 molecular diagnostic tests specialized in Leukemia early diagnostic, treatment guidance and MRD (Minimal residual disease) monitoring.